Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP

Transcription

1 Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP

2 I do not have any relevant financial relationships with any commercial interests.

3 At the end of this presentation, participants will be able to: Discuss the Federal Bureau of Prisons Guidelines for the treatment of HCV with protease inhibitors. Describe barriers to effective HCV treatment in the correctional setting. Outline key decisions needed to implement an effective HCV treatment program in the correctional setting.

4 HCV identified late 1980 s. 3.2 million Americans with chronic infx. Genotypes identified ,2,3, (4,5,6-less common) Genotype 1 most common in US (⅔ to ¾ of cases) Natural history 1/5 resolve spontaneously 3/5 develop chronic infx but no sequelae 1/5 with chronic infx develop cirrhosis / complications More die from HCV now than from HIV (15,000 + / yr) ½ of HCC deaths from HCV Most common reason for liver transplant Direct medical costs > $6.7 billion ( )

5

6 PIs bocepravir and telapravir were approved in 2011 for combination therapy WITH peginterferon/ribavirin Improved response rates for genotype 1 Improves from 40% to (67% - 75%)

7 SVR rates 20 to 40% compared to pegifn + RBV! Overall (70-80%) Treatment naïve (67-75%) African-American (62%) Advanced fibrosis (62%) High viral load (74%) Relapser (69-88%) Partial responder (40-59%) Null responder (23-38% with telaprevir based tx) HCV Protease Inhibitor Trials Boceprevir SPRINT 1/2; RESPOND 2 Telaprevir ADVANCE, ILLUMINATE, PROVE 1/2; REALIZE

8 Treatment of chronic HCV, genotype 1 - Not approved for tx of other HCV genotypes In combination with pegifn + RBV - Not approved for monotherapy Treatment naïve or prior tx failures with pegifn/rbv - Relapse, partial or null response. - Re-tx of null responders not studied with BOC - SVR rates for prior null responders < 30% to 40%

9 Viral Resistance IFN / RBV do not produce resistance. Viral mutations Resistance to HCV PIs Treatment failure = viral resistance. 80% to 90% correlation. Non-adherence viral resistance. Viral resistance appears to be class effect - Cannot switch from one HCV PI to another for tx failure.

10 Phase IIa study of only 21 pts with hepatitis C who failed prior tx with peginterferon/ribavirin Tx with oral NS5A replication complex inhibitor (daclatasvir) and oral NS3 protease inhibitor (asunaprevir) with or without addition of peginterferon/ribavirin 4/11 responded to two oral drug combination alone an unprecedented finding 10/10 responded with two oral drugs + PI/R

11 Scores of investigational drugs in the pipeline for HCV treating. Most are direct acting antiviral agents that attack HCV encoded proteins protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors. Others attack host-encoded factors important for HCV replication cyclophilin inhibitors, microrna-122 inhibition Movement toward all oral, simpler regimens with higher efficacy HIV de ja vu?

12 Define evidenced-based practice Apply to patient population Issue Clinical Practice Guideline Provider user friendly tools Educate practitioners Implement TEAM Medicine approach Establish loci of control as warranted Evaluate delivery of care Improve delivery of care

13 1. Appropriately screen for HCV (anti-hcv by EIA or CIA) 2. Provide initial medical follow-up for HCV + inmates 3. Determine if HCV Tx is not recommended 4. Obtain HCV RNA assay and genotype 5. Assess liver fibrosis and need for a liver biopsy 6. Determine if treatment should be initiated 7. Conduct a pre-treatment evaluation 8. Determine appropriate tx / obtain informed consent 9. Monitor treatment / manage side effects 10. Assess for SVR 6 months after treatment completion

14 Complex Medication Regimens / Decision Points Duration of treatment determined by 4 variables HCV treatment history - Tx naïve vs. relapser vs. partial responder vs. null responder Fibrosis stage - Compensated cirrhosis treated for 48 weeks Which HCV PI is prescribed - Tx algorithm is different for each HCV PI Response to treatment - a.k.a. Response Guided Therapy (RGT)

15

16 28 wks (total) 4 weeks pegifn+ RBV (DT) followed by 24 weeks of BOC + pegifn + RBV (TT) If tx naïve & RNA undetectable (-) at 8 & 24 wks 36 weeks (total) 4 wks DT + 32 wks TT If prior relapser / partial responder & RNA (-) at 8 & 24 wks 48 wks (total) 4 wks DT + 32 wks TT + 12 wks DT If tx naïve, prior relapser or partial responder AND RNA (+) after week 8 but (-) after TW 24 If & RNA (+) at 8 but (-) at 24 wks 48 wks (total) 4 wks DT + 44 wks TT If compensated cirrhosis

17 Stop all HCV meds if HCV RNA is 100 IU/ml at 12 wks or detectable (+) at 24 wks or by > 1 log 10 above treatment nadir *a.k.a. Futility Rules

18

19

20 First 12 weeks Triple Therapy with TVR + pegifn + RBV TVR dose = 750 mg (two 375 mg tabs) PO q 8 hr (+/- 1hr) Each dose must be taken with 20 gm fat snack pegifn + RBV, standard dosing. D/C all meds if RNA > 1,000 IU/ml at 4 or 12 weeks or > 1 log increase from treatment nadir Continue pegifn + RBV for 24 or 48 weeks (total) 24 wks total if Tx naïve or relapser AND RNA undetectable at 4 & 12wks. 48 wks total if Treatment naïve or relapser AND HCV RNA (+) but 1,000 at 4 and 12 wks & undetectable at 24 wks Compensated cirrhosis or prior partial responder AND HCV RNA 1,000 at 4 and 12 wks & undetectable at 24 wks

21 D/C all meds if HCV RNA is > 1000 IU/ml at 4 or 12 weeks or Detectable at 24 weeks or Increased by > 1 log 10 above treatment nadir. *a.k.a. Futility Rules

22

23 Medication side effects PegIFN and RBV side effects Boceprevir (BOC) Anemia Dysgeusia Telaprevir (TVR) Anemia Rash / Pruritus GI / anorectal Dysgeusia Hyperuricemia

24 Cost (FSS or FSR) Boceprevir + pegifn/rbv (PR) PR 28 / BOC 24 = $23,000 PR 36 / BOC 32 = $30,400 PR 48 / BOC 32 = $32,500 PR 48 / BOC 44 = $41,537 Telaprevir + PR TPV 12 / PR 24 = $39,400 TPV 12 / PR 48 = $43,700

25 HCV Genotype 1 with stage 2 fibrosis on liver biopsy Prioritize higher stages of fibrosis, e.g. stages 3 & 4 Consider / discuss deferring tx for lower stages of fibrosis, e.g. stage 2 newer agents likely in 2 to 5 yrs. No contraindications /exclusions. Highly motivated and compliant. Continuity of care for new intakes on triple tx. With appropriate assessment following intake. Prior null responders to DT considered on caseby-case basis.

26 Comorbid medical conditions Cardiovascular or metabolic conditions E.g. known coronary heart disease, DM, hyperlipidemia, or hyperuricemia/gout Telaprevir requires 20 gm fat snack 3x/day and increases uric acid levels; Anorectal conditions E.g. hemorrhoids, proctitis, diarrhea increased incidence of anorectal symptoms with telaprevir Dermatologic conditions E.g. eczema, psoriasis Increased incidence of rash with telaprevir. Lower fibrosis score E.g. stage 2/4 more likely to meet criteria for shorter course of therapy BOC is cheaper / more cost effective with shorter treatment durations. Medication contraindications (CI) with telaprevir e.g. atorvastatin is CI with telaprevir but use with caution in BOC.

27 Short Course of BOC not indicated Compensated cirrhosis or prior treatment failures with pegifn/rbv Prior null responders not studied in BOC trials. Simpler TVR regimen could improve adherence; Cost advantage with BOC is lost with longer BOC tx course. Medication contraindications with BOC e.g. carbamazepine, phenobarbital, and phenytoin are CI with BOC but labeled as use with caution with TVR. Borderline acceptable hemoglobin levels Hgb decreased but not at contraindicated levels BOC studies used ESAs (erythropoietin stimulating agents) in up to 50% of cases whereas TVR studies did not use ESAs and discontinuation rates were similar).

28 HCV PIs must be taken q 8 hr (+/- 1 hr) with food Continue BID pill line for RBV and weekly pegifn injx as per current local procedures. Dispense weekly supply of HCV PI Inmate must return empty bottles / blisters each wk. Remote fill requested 1 week prior. Treating clinician sends request for supplemental feeding (3 times / day) to FSA. TVR 20 gm fat snack (3 TBSP peanut butter or 2 slices cheese with bread or crackers) BOC taken with a meal or light snack, per policy.

29

30 Sample Lab Planner which can autopopulate dates due for labs based on treatment start date

31 HCV RNA schedule Baseline, end of tx, & 24 wks after ETR BOC treatment weeks 4, 8, 12, 24 TVR treatment wks 4, 12, 24 Report interpretation Futility: > 1000 IU/ml wk 4 or wk 12 (TVR); or 100 IU/ml wk 12 (BOC). Detectable vs. Undetectable Timely drawing and result reporting is essential

32 Transfer issues Place medical hold on patients during treatment to prevent treatment interruptions. Patient education is essential Treatment regimen and adherence Side effects Medication interactions / pregnancy issues Option to postpone therapy if stage 2 fibrosis Cannot transfer or release during treatment Have patient sign Hep C tx consent form

33 Utilizing a multidisciplinary team helps navigate the complexities of HCV treatment BOP is utilizing Regional HCV Clinical Pharmacist Consultants to work in conjunction with health services staff at the local level to provide guidance on the new HCV protease inhibitors and optimize patient outcomes, while promoting cost efficiencies.

34 Start date: October 1, Regional Hepatitis Clinical Pharmacists and Hepatitis Program Manager 3 General Goals Ensure appropriate, cost effective, and safe treatment for HCV. Determine treatment efficacy for HCV. Enhance / Improve Screening and Diagnostic Evaluations to identify patients with chronic HCV infections who might be appropriate candidates for treatment.

35 Non-formulary requests approved for tx for boceprevir 72 for telaprevir 160 started on treatment; 107 active on tx; 22 completed tx (19 with ETR, 3 relapse) 31 discontinued; 9 due to virologic failure; 12 due to patient non-compliance or refusal; 10 due to hematologic factors (anemia, neutropenia, thrombocytopenia) despite INF/RBV dose adjustment Too early to assess overall efficacy

36 Patient education / informed consent is critical Tracking snack intake is important Telaprevir requires uric acid monitoring 8 week HCV viral load for boceprevir is crucial Lack of timely laboratory monitoring can be dangerous for the patient and costly when treatment fails Major side effects noted: anemia, neutropenia, and rash Quality control is absolutely critical as there are multiple ways of making mistakes in treatment regimen / monitoring.

37 Treatment is very expensive ensure guidelines and administrative controls are in place Treatment is extraordinarily complicated consolidate treatment centers where feasible, implement algorithms/monitoring tools, and adopt quality control measures Await newer treatment options to include simpler, possible all oral regimens in the future Anticipate more personalized approach to treatment based on genetic host factors

38